348 related articles for article (PubMed ID: 18753925)
1. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients.
;
AIDS; 2008 Sep; 22(14):F17-24. PubMed ID: 18753925
[TBL] [Abstract][Full Text] [Related]
2. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration.
; Sabin CA; Worm SW; Weber R; Reiss P; El-Sadr W; Dabis F; De Wit S; Law M; D'Arminio Monforte A; Friis-Møller N; Kirk O; Pradier C; Weller I; Phillips AN; Lundgren JD
Lancet; 2008 Apr; 371(9622):1417-26. PubMed ID: 18387667
[TBL] [Abstract][Full Text] [Related]
3. Risk of cardiovascular events from current, recent, and cumulative exposure to abacavir among persons living with HIV who were receiving antiretroviral therapy in the United States: a cohort study.
Dorjee K; Baxi SM; Reingold AL; Hubbard A
BMC Infect Dis; 2017 Oct; 17(1):708. PubMed ID: 29078761
[TBL] [Abstract][Full Text] [Related]
4. Heart attack risk with abacavir and didanosine.
AIDS Patient Care STDS; 2008 Apr; 22(4):346-7. PubMed ID: 18434947
[No Abstract] [Full Text] [Related]
5. Metabolic events in HIV-infected patients using abacavir are associated with erythrocyte inosine triphosphatase activity.
Peltenburg NC; Bierau J; Schippers JA; Lowe SH; Paulussen ADC; van den Bosch BJC; Leers MPG; Andrinopoulou ER; Bakker JA; Verbon A
J Antimicrob Chemother; 2019 Jan; 74(1):157-164. PubMed ID: 30304447
[TBL] [Abstract][Full Text] [Related]
6. FDA notifications. Large study suggests heart attack risk from use of abacavir or didanosine.
AIDS Alert; 2008 May; 23(5):58-9. PubMed ID: 18642404
[No Abstract] [Full Text] [Related]
7. K65R with and without S68: a new resistance profile in vivo detected in most patients failing abacavir, didanosine and stavudine.
Røge BT; Katzenstein TL; Obel N; Nielsen H; Kirk O; Pedersen C; Mathiesen L; Lundgren J; Gerstoft J
Antivir Ther; 2003 Apr; 8(2):173-82. PubMed ID: 12741630
[TBL] [Abstract][Full Text] [Related]
8. Abacavir: a review of its clinical potential in patients with HIV infection.
Hervey PS; Perry CM
Drugs; 2000 Aug; 60(2):447-79. PubMed ID: 10983741
[TBL] [Abstract][Full Text] [Related]
9. Use of Abacavir and Risk of Cardiovascular Disease Among HIV-Infected Individuals.
Marcus JL; Neugebauer RS; Leyden WA; Chao CR; Xu L; Quesenberry CP; Klein DB; Towner WJ; Horberg MA; Silverberg MJ
J Acquir Immune Defic Syndr; 2016 Apr; 71(4):413-9. PubMed ID: 26536316
[TBL] [Abstract][Full Text] [Related]
10. Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era.
Bedimo RJ; Westfall AO; Drechsler H; Vidiella G; Tebas P
Clin Infect Dis; 2011 Jul; 53(1):84-91. PubMed ID: 21653308
[TBL] [Abstract][Full Text] [Related]
11. Abacavir, didanosine and tenofovir do not induce inflammatory, apoptotic or oxidative stress genes in coronary endothelial cells.
Kim C; Gupta SK; Green L; Taylor BM; Deuter-Reinhard M; Desta Z; Clauss M
Antivir Ther; 2011; 16(8):1335-9. PubMed ID: 22155915
[TBL] [Abstract][Full Text] [Related]
12. Abacavir does not affect circulating levels of inflammatory or coagulopathic biomarkers in suppressed HIV: a randomized clinical trial.
Martin A; Amin J; Cooper DA; Carr A; Kelleher AD; Bloch M; Baker D; Woolley I; Emery S;
AIDS; 2010 Nov; 24(17):2657-63. PubMed ID: 20827168
[TBL] [Abstract][Full Text] [Related]
13. [Toxic epidermal necrolysis associated with abacavir].
Montero M; García-Gibert L; Giménez-Arnau AM; Knobel H
Enferm Infecc Microbiol Clin; 2005 Apr; 23(4):247. PubMed ID: 15826554
[No Abstract] [Full Text] [Related]
14. Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone.
Jones R; Sawleshwarkar S; Michailidis C; Jackson A; Mandalia S; Stebbing J; Bower M; Nelson M; Gazzard BG; Moyle GJ
HIV Med; 2005 Nov; 6(6):396-402. PubMed ID: 16268821
[TBL] [Abstract][Full Text] [Related]
15. Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA.
Clumeck N; Goebel F; Rozenbaum W; Gerstoft J; Staszewski S; Montaner J; Johnson M; Gazzard B; Stone C; Athisegaran R; Moore S;
AIDS; 2001 Aug; 15(12):1517-26. PubMed ID: 11504984
[TBL] [Abstract][Full Text] [Related]
16. Abacavir and risk of myocardial infarction in HIV-infected patients on highly active antiretroviral therapy: a population-based nationwide cohort study.
Obel N; Farkas DK; Kronborg G; Larsen CS; Pedersen G; Riis A; Pedersen C; Gerstoft J; Sørensen HT
HIV Med; 2010 Feb; 11(2):130-6. PubMed ID: 19682101
[TBL] [Abstract][Full Text] [Related]
17. Inflammatory biomarkers and abacavir use in the Women's Interagency HIV Study and the Multicenter AIDS Cohort Study.
Palella FJ; Gange SJ; Benning L; Jacobson L; Kaplan RC; Landay AL; Tracy RP; Elion R
AIDS; 2010 Jul; 24(11):1657-65. PubMed ID: 20588104
[TBL] [Abstract][Full Text] [Related]
18. A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II).
Eron JJ; Murphy RL; Peterson D; Pottage J; Parenti DM; Jemsek J; Swindells S; Sepulveda G; Bellos N; Rashbaum BC; Esinhart J; Schoellkopf N; Grosso R; Stevens M
AIDS; 2000 Jul; 14(11):1601-10. PubMed ID: 10983647
[TBL] [Abstract][Full Text] [Related]
19. Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment.
Keiser PH; Sension MG; DeJesus E; Rodriguez A; Olliffe JF; Williams VC; Wakeford JH; Snidow JW; Shachoy-Clark AD; Fleming JW; Pakes GE; Hernandez JE;
BMC Infect Dis; 2005 Jan; 5():2. PubMed ID: 15647105
[TBL] [Abstract][Full Text] [Related]
20. HIV-1 reverse transcriptase and protease resistance mutations selected during 16-72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/amprenavir in the CNA2007 study.
Ait-Khaled M; Rakik A; Griffin P; Stone C; Richards N; Thomas D; Falloon J; Tisdale M;
Antivir Ther; 2003 Apr; 8(2):111-20. PubMed ID: 12741623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
